The combination of HDAC and MEK inhibitors as a chemotherapeutic strategy in tumors was first proposed in a study that showed MEK inhibitors sensitized colon, lung and prostate cancer cells to HDACi-induced cell death [42]. Here, HDAC9 is linked to prostate cancer.